Position in NVAX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$126,322
-$581,190 QoQ
Shares Held
13,410
-84.6% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#154
of 263 holders
Holding Since
Jun 2021
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Bridgefront Capital, LLC holds $16,100,567 across 34 Biotechnology names. NVAX ranks #34 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
16,808 | $1,792,068 | |
| 2 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
11,282 | $1,252,640 | |
| 3 | AGIO |
Agios Pharmaceuticals, Inc.
|
31,097 | $1,154,009 | |
| 4 | TECH |
BIO-TECHNE Corp
|
15,017 | $1,060,951 | |
| 5 | SMMT |
Summit Therapeutics Inc.
|
60,416 | $880,261 | |
| 6 | BHVN |
Biohaven Ltd.
|
51,351 | $764,102 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
19,746 | $698,810 | |
| 8 | ELVN |
Enliven Therapeutics, Inc.
|
12,096 | $613,872 |
All Filings in NVAX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $126,322 | 13,410 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $707,512 | 86,918 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $145,551 | 16,788 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $232,199 | 36,857 | Shares | Sole | 2025-08-14 | |
| 2022-12-31 | $108,690 | 10,573 | Shares | Sole | 2023-02-15 | |
| 2021-12-31 | $200,727 | 1,403 | Shares | Sole | 2022-02-10 | |
| 2021-06-30 | $299,781 | 1,412 | Shares | Sole | 2021-08-12 | |
| No filing history on record for this holder in this stock. | ||||||